Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease
ConclusionSustained long-term remissions can be achieved in patients with early relapse of DLBCL following ASCT in a second or third treatment line, particularly in patients with low- and low-intermediate-risk IPI, following radiotherapy of residual disease after ASCT. Further investigations are required to clarify which patients need an alternative therapy (potentially CAR T‑cells or allogeneic transplantati on).
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Alternative and Complementary Therapies | Cancer & Oncology | Chemotherapy | Lymphoma | Stem Cell Therapy | Stem Cells | Study | Transplants